Provided by Tiger Trade Technology Pte. Ltd.

Veru Inc.

2.42
+0.07002.98%
Volume:86.06K
Turnover:207.45K
Market Cap:38.84M
PE:-2.03
High:2.50
Open:2.32
Low:2.32
Close:2.35
52wk High:7.40
52wk Low:2.10
Shares:16.05M
Float Shares:14.48M
Volume Ratio:1.07
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1898
EPS(LYR):-1.5517
ROE:-60.25%
ROA:-42.92%
PB:1.05
PE(LYR):-1.56

Loading ...

Analysts Are Bullish on These Healthcare Stocks: CAMP4 Therapeutics Corporation (CAMP), Veru (VERU)

TIPRANKS
·
Feb 16

Canaccord Genuity Sticks to Its Buy Rating for Veru (VERU)

TIPRANKS
·
Feb 12

Veru Inc. Charts Risky but Clearer Post-GLP-1 Path

TIPRANKS
·
Feb 12

Veru Q1 EPS $(0.26) Beats $(0.47) Estimate

Benzinga
·
Feb 11

Veru Inc. Q1 R&D expenses fall 76% to USD 1.34 million

Reuters
·
Feb 11

Press Release: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Dow Jones
·
Feb 11

Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an

Reuters
·
Feb 04

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

GlobeNewswire
·
Feb 04

Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting

Reuters
·
Feb 04

Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting

Reuters
·
Jan 29

Veru Initiated at Buy by Canaccord Genuity

Dow Jones
·
Dec 18, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-Veru rises after US FDA backs obesity drug combo plan

Reuters
·
Dec 17, 2025

Veru FY 2025 EPS $(1.55) Beats $(1.77) Estimate

Benzinga
·
Dec 17, 2025

Veru Inc. FY2025 net loss narrows to USD 22.7 million, down 40 percent

Reuters
·
Dec 17, 2025

Veru Inc - Company Plans to Initiate Phase 2 Plateau Clinical Study in Calendar Q1 2026

THOMSON REUTERS
·
Dec 17, 2025

Veru Inc - FY Net Loss From Cont Ops Decreased to $15.7 Mln or $1.07 per Share

THOMSON REUTERS
·
Dec 17, 2025

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

THOMSON REUTERS
·
Dec 17, 2025

Veru Inc - Received FDA Regulatory Clarity for Enobosarm in Combination With Glp-1 Ra

THOMSON REUTERS
·
Dec 17, 2025